Moderna Inc said it will apply for U.S. and European emergency authorization of its COVID-19 vaccine on Monday based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns. It also reported a 100% success rate in preventing severe cases. The filing sets Moderna's product up to be the second vaccine likely to receive U.S.